HeyJaredPeter Loftus
- Indexed articles, last 90 days
- 1
- Latest publication
- Jul 15, 2026
- Outlet visibility, for Livemint
- Top 10K sites
- Earliest in this view
- Jul 15, 2026
Latest articles
In the weight-loss wars, Novo’s obesity pill is pulling way ahead of Lilly’s | Mint (opens the original)
Read excerpt
This is a Mint Premium article gifted to you.Subscribe to enjoy similar stories. The launch of weight-loss pills is the hottest battle in pharma. So far, Eli Lilly is losing to rival Novo Nordisk. Since its obesity pill Foundayo hit the market in April, Lilly has captured about 11% of the prescription volume for new pills, according to the latest weekly data. Novo Nordisk’s Wegovy pill, which launched in January, commands the rest. It is a remarkable turn of events for the near $80 billion anti-
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 10K sites
For Livemint, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.